Protein linked to cell death may also drive liver cancer
· Medical Xpressedited by Gaby Clark, reviewed by Andrew Zinin
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
New research from the University of Oklahoma identifies a protein in liver cells that appears to help drive the development of liver cancer associated with obesity-related fatty liver disease. The finding, published in Hepatology, points to the protein as a potential new therapeutic target for liver cancer.
The protein, MLKL (mixed lineage kinase domain-like protein), is best known for its role in necroptosis, a form of cell death. In this study, MLKL levels increased in mice fed a Western-style (high-fat) diet. However, rather than causing liver cell death, MLKL appears to reduce the function of mitochondria, the structures inside cells that produce energy, and promote tumor development in the liver. When MLKL was removed from liver cells in mice, fewer and smaller liver tumors developed.
"This finding was very surprising because it reveals a new role for MLKL, and it suggests that MLKL could be a therapeutic target for hepatocellular carcinoma, a primary form of liver cancer. We are excited to continue investigating whether targeting this protein could slow or prevent tumor growth," said senior author Deepa Sathyaseelan, Ph.D., associate professor of biochemistry and physiology in the OU College of Medicine. She is also a member of OU Health Stephenson Cancer Center and OU Health Harold Hamm Diabetes Center.
The mechanism by which MLKL promotes tumor development involves another protein, MFN2 (mitofusin 2), which helps maintain healthy mitochondria. When MLKL increases in response to a high-fat diet, MFN2 decreases, thereby impairing mitochondrial function. In the absence of MLKL, MFN2 levels return, improving mitochondrial function and leading to reduced tumor growth.
"Research has already shown us that mitochondrial dysfunction is a key driver for several liver diseases, including liver cancer," Sathyaseelan said. "Our research identifies a mechanism by which that dysfunction occurs."
Another surprising aspect of the research is that, even though the mice had fewer and smaller tumors when MLKL was absent, removing MLKL did not reduce fatty liver, liver inflammation, fibrosis or liver injury.
"Traditionally, we have considered liver cancer a progressive disease," she said. "What we expected to see (with the removal of MLKL) was a reduction in fatty liver, a reduction in fibrosis and, eventually, a reduction in liver tumors. But that's not what we found. It tells us that MLKL is regulating tumor development through a completely different pathway. That means we may have the potential to directly target liver cancer, which is good news because it is often not discovered until its later stages."
In addition to experiments in mice and laboratory-grown liver cancer cells, Sathyaseelan's team analyzed human liver cancer data sets and tumor samples. They found that tumors with higher levels of MLKL were associated with poorer overall survival.
Sathyaseelan and her team plan to continue studying MLKL as a potential therapeutic target, including investigating MLKL inhibitors and whether they could be combined with existing cancer treatments. They also plan to study whether MLKL can serve as a biomarker for liver cancer.
"Nearly 30 percent of the U.S. adult population has fatty liver disease," she said. "For people who progress to liver cancer, the five-year overall survival is approximately 22%, and current therapies are not very effective. In years past, liver cancer was primarily caused by hepatitis B or C infections or chronic alcoholism. Now fatty liver disease is a major contributor. That's why we need to understand the basic mechanism by which a fatty liver progresses to liver cancer."
Publication details
Phoebe Ohene-Marfo et al, Hepatocyte MLKL drives obesity-driven hepatocellular carcinoma progression via mitochondrial dysfunction independent of necroptosis in MASLD, Hepatology (2026). DOI: 10.1097/hep.0000000000001830
Journal information: Hepatology
Key medical concepts
Carcinoma, HepatocellularNecroptosis
Clinical categories
OncologyGastroenterology Provided by University of Oklahoma Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Protein linked to cell death may also drive liver cancer (2026, September 10) retrieved 10 September 2026 from https://medicalxpress.com/news/2026-09-protein-linked-cell-death-liver.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.